Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
|Videos|December 22, 2020
Manageable and In Control
Author(s)Susan J. Noonan, MD, MPH
Daily routine and structure will decrease a patient's stress and give them a sense of accomplishment.
Advertisement
Susan Noonan, MD, MPH, talks how small, broken down tasks and a system will help patients maintain their mental health.
Dr Noonan is a physician consultant and Certified Peer Specialist in the Department of Psychiatry at McLean Hospital and the Massachusetts General Hospital. She is the author of four books and a blog on managing depression, most recently
Advertisement
Related to this article
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
Advertisement
Advertisement
Trending on Psychiatric Times
1
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
2
Death, Taxes, and Envy: Treating Creative Patients
3
Schizophrenia: A Telltale of the Brain’s Complexity
4
Cannabis Use Prevalent In Substance-Related Adolescent Emergency Care: Insights From Kevin Xu, MD
5